Surgical Oncology-Oxford最新文献

{"title":"Sustained high neutrophil-to-lymphocyte ratio during neoadjuvant chemotherapy predicts worse prognosis in patients after esophagectomy for esophageal squamous cell carcinoma","authors":"Keita Takahashi,&nbsp;Masami Yuda,&nbsp;Yoshitaka Ishikawa,&nbsp;Takanori Kurogochi,&nbsp;Akira Matsumoto,&nbsp;Naoko Fukushima,&nbsp;Takahiro Masuda,&nbsp;Kazuto Tsuboi,&nbsp;Fumiaki Yano,&nbsp;Ken Eto","doi":"10.1016/j.suronc.2025.102335","DOIUrl":"10.1016/j.suronc.2025.102335","url":null,"abstract":"<div><h3>Purpose</h3><div>The contribution of the trend of neutrophil-to-lymphocyte ratio (NLR) values during neoadjuvant chemotherapy (NAC) remains poorly understood in patients with esophageal squamous cell carcinoma (ESCC). Thus, this study aimed to clarify the influence of sustained-high-NLR during NAC on the prognosis of ESCC patients undergoing curative esophagectomy after NAC.</div></div><div><h3>Methods</h3><div>This study analyzed 108 ESCC patients. Patients were divided into four groups as the remained-low-NLR group, the elevated-NLR group, the decreased-NLR group, and the sustained-high-NLR group according to the NLR levels before and after NAC. After that, the backgrounds and perioperative factors were compared among the four groups. Finally, Independent prognostic factors were identified.</div></div><div><h3>Results</h3><div>The overall survival (OS) was significantly different among the four groups (p = 0.02) and relapse-free survival (RFS) tended to be different among the groups (p = 0.08), with the sustained-high-NLR group having the poorest survival. In a multivariate analysis for OS and RFS, sustained-high-NLR was a significant adverse prognostic factor (p &lt; 0.01; HR, 3.16; 95 % CI, 1.38–7.22 and p = 0.01; HR, 2.45; 95 % CI, 1.22–4.93, respectively).</div></div><div><h3>Conclusions</h3><div>Consistently elevated NLR during NAC was correlated with an unfavorable prognosis in patients who underwent NAC followed by esophagectomy for ESCC. Additionally, sustainedly high NLR may be a useful biomarker for adjuvant nivolumab.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102335"},"PeriodicalIF":2.4,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145693709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinically significant delayed gastric emptying after multivisceral resection for retroperitoneal sarcoma: A retrospective cohort study","authors":"Dorian Yarih Garcia-Ortega ,&nbsp;Luis Antonio Bonilla-Salado ,&nbsp;Ana Paulina Meléndez-Fernández ,&nbsp;Sylvia Veronica Villavicencio-Valencia ,&nbsp;Diyitzia Rosario Irineo-Cerecedo ,&nbsp;Cherilynn Martinez-Valdovinos ,&nbsp;David Aarón Bujanda-Sandoval ,&nbsp;Kuauhyama Luna-Ortiz","doi":"10.1016/j.suronc.2025.102336","DOIUrl":"10.1016/j.suronc.2025.102336","url":null,"abstract":"<div><h3>Background</h3><div>Delayed gastric emptying (DGE) is an underrecognized but clinically impactful complication following multivisceral resection (MVR) for retroperitoneal sarcoma (RPS). This study aimed to determine the incidence, risk factors, and postoperative morbidity of clinically significant DGE in a Latin American tertiary referral sarcoma center.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of adult patients with primary or recurrent RPS who underwent MVR between January 2020 and December 2024. DGE was defined and graded according to ISGPS criteria, with grades B–C considered clinically significant. Multivariable logistic regression identified independent predictors for DGE. Clinical outcomes were compared by DGE status.</div></div><div><h3>Results</h3><div>Among 142 patients who underwent MVR, the incidence of clinically significant DGE was 8.6 %. Independent risk factors included tumor size &gt;22 cm (OR 2.25; 95 % CI 1.12–4.50; p = 0.023), dedifferentiated liposarcoma histology (OR 3.52; 95 % CI 1.12–11.01; p = 0.031), and multifocal disease (OR 2.78; 95 % CI 1.03–7.49; p = 0.044). DGE was associated with a prolonged hospital stay (22 vs. 10.5 days, p &lt; 0.001) and a higher rate of ICU admission (9.3 % vs. 2.7 %, p = 0.034). No significant associations were found with major complications or reoperation.</div></div><div><h3>Conclusions</h3><div>Clinically significant DGE is an infrequent but high-impact complication after MVR for RPS. Tumor-related features such as large size, high-grade histology, and multifocality contribute to its development. Early identification and standardized perioperative strategies may help reduce the incidence and clinical burden of this condition. These findings provide essential data from a historically underrepresented region and support efforts to optimize postoperative recovery in complex sarcoma surgery.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102336"},"PeriodicalIF":2.4,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of TRACP 5b as a local recurrence biomarker in giant cell tumor of bone","authors":"Yu Toda,&nbsp;Koichi Ogura,&nbsp;Shintaro Iwata,&nbsp;Eisuke Kobayashi,&nbsp;Shuhei Osaki,&nbsp;Suguru Fukushima,&nbsp;Akira Kawai","doi":"10.1016/j.suronc.2025.102331","DOIUrl":"10.1016/j.suronc.2025.102331","url":null,"abstract":"<div><h3>Background</h3><div>Giant cell tumor of bone (GCTB) has a high potential for local recurrence after surgical treatment. It is characterized by the histological proliferation of osteoclast-like multinucleated giant cells. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a reliable serum marker of bone resorption. This study aimed to investigate the impact of TRACP5b levels on the local recurrence of GCTB following surgical treatment.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed data from 47 primary GCTB patients who underwent serum TRACP5b testing and surgical treatment between 2015 and 2022. We statistically evaluated the correlation between TRACP5b levels and clinical characteristics. Patients were stratified into two groups based on TRACP5b levels, and the association between TRACP5b and local recurrence was assessed across various clinical parameters.</div></div><div><h3>Results</h3><div>The mean TRACP5b level in male patients (2062 ± 2289 mU/dL) was significantly higher than in female patients (976 ± 487 mU/dL; p = 0.048). A moderate positive correlation was observed between tumor size and TRACP5b levels (r = 0.586, p &lt; 0.001). Gender, tumor location (trunk, lower extremity, and upper extremity), tumor size, and TRACP5b levels were significantly associated with local recurrence-free survival (p values were 0.037, 0.0006, 0.048, and 0.004, respectively).</div></div><div><h3>Conclusions</h3><div>This study identified preoperative TRACP5b levels as a prognostic factor for local recurrence in GCTB patients, highlighting its potential utility in risk stratification and personalized management.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102331"},"PeriodicalIF":2.4,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical management of breast cancer liver metastases: what indications and results in 2025? A narrative review","authors":"Lucia Paiano ,&nbsp;René Adam ,&nbsp;Nicolas Golse","doi":"10.1016/j.suronc.2025.102330","DOIUrl":"10.1016/j.suronc.2025.102330","url":null,"abstract":"<div><div>Breast cancer liver metastases (BCLM) have historically been treated with chemotherapy and supportive care, and long-term survival in stage IV breast cancer remains rare despite advances in systemic therapies such as chemotherapy, hormonal and targeted therapies. Since the 2000s, many trials comparing surgery and systemic therapy have improved our understanding of the management of BCLM. Prognostic factors influencing outcome include disease-free interval from primary tumor, hormone receptor status, metastatic burden and tumor biology. Molecular profiling (e.g. BRCA1/2, PIK3CA, HER2, ESR1) has further refined the response to systemic therapy, enabling personalized treatment strategies. Recent evidence highlights the prognostic impact of surgery in combination with systemic therapy in highly selected patients, with a 5-year survival rate reaching 53 %. Optimal surgical candidates may include patients with small (&lt;5 cm), solitary or easily resectable metastases, stable disease on neoadjuvant therapy and favorable tumor biology. However, preoperative imaging often underestimates tumor burden, leading to resection cancellation in ∼20 % of cases. Unlike colorectal liver metastases, BCLM rarely become resectable after systemic therapy, which is primarily aimed at disease control and reducing recurrence risk. Non-surgical interventions, including radiofrequency or microwave ablation and radioembolization, are typically reserved for patients who are ineligible for surgery due to frailty, comorbidities or challenging tumor locations. Multidisciplinary planning remains essential to optimize treatment, integrating systemic advances, tumor biology and surgical feasibility to improve long-term outcomes in the management of BCLM.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102330"},"PeriodicalIF":2.4,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145623776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies of the management of pulmonary metastases in children with Ewing sarcoma- single institution experience of 137 patients","authors":"Krzysztof Bronowicki,&nbsp;Justyna Antoniuk-Majchrzak,&nbsp;Iwona Malesza,&nbsp;Tomasz Walenta,&nbsp;Agnieszka Szymborska,&nbsp;Anna Raciborska","doi":"10.1016/j.suronc.2025.102334","DOIUrl":"10.1016/j.suronc.2025.102334","url":null,"abstract":"<div><h3>Background</h3><div>The role of pulmonary metastasectomy in pediatric Ewing sarcoma remains controversial, with significant treatment selection bias complicating the interpretation of retrospective series.</div></div><div><h3>Objective</h3><div>To evaluate treatment outcomes in isolated pulmonary metastases (PM) using propensity score analysis to control for selection bias.</div></div><div><h3>Methods</h3><div>Retrospective analysis of 137 patients with pulmonary metastases (85 isolated PM, 52 PM with extrapulmonary metastases) treated between 1998 and 2024. Primary comparison focused on thoracotomy alone versus radiotherapy alone in isolated PM patients with primary tumor surgery (n = 30). Propensity score matching was performed to address selection bias.</div></div><div><h3>Results</h3><div>Patients with isolated PM had superior overall survival compared to those with extrapulmonary disease (median OS: 111 vs 66 months, p &lt; 0.001). In isolated PM patients with primary tumor surgery, direct comparison between thoracotomy alone and radiotherapy alone revealed superior survival with surgical resection (median OS: 125 vs 38 months, p = 0.009).</div><div>Stratified analysis by chemotherapy response demonstrated that thoracotomy benefit was primarily evident in patients with poor histologic response (≤10 % viable cells, median OS: 56 vs 27 months, p = 0.017), while patients with good response showed similar outcomes regardless of local treatment approach (p = 0.104).</div><div>After propensity score matching and multivariable adjustment for age and gender, the apparent benefit of thoracotomy was maintained in direct treatment comparisons, though overall comparison against all non-surgical treatments showed no significant difference (HR 0.75, p = 0.343), highlighting the importance of appropriate treatment comparisons and patient selection.</div></div><div><h3>Conclusions</h3><div>Thoracotomy may benefit carefully selected isolated PM patients, particularly those with poor response to chemotherapy. However, significant selection bias complicates the interpretation of retrospective surgical series. The benefit appears limited to specific clinical scenarios rather than representing a general therapeutic advantage. Future studies should focus on developing standardized selection criteria and prospective validation of treatment algorithms.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102334"},"PeriodicalIF":2.4,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145693723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between preoperative inflammatory status and survival in patients undergoing curative surgery for colorectal cancer","authors":"Valerio Argiolas ,&nbsp;Simona Deidda ,&nbsp;Mirko Armas,&nbsp;Luigi Zorcolo,&nbsp;Angelo Restivo","doi":"10.1016/j.suronc.2025.102332","DOIUrl":"10.1016/j.suronc.2025.102332","url":null,"abstract":"<div><h3>Introduction</h3><div>Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide. While TNM staging remains the cornerstone for prognostic stratification, growing evidence highlights the role of systemic inflammation and nutritional status in influencing oncologic outcomes. This study aimed to evaluate the prognostic significance of preoperative immunonutritional indices in patients undergoing curative resection for stage I–III CRC.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included 616 patients treated between January 2013 and December 2021 at a single tertiary center. Preoperative indices—neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), prognostic nutritional index (PNI), and systemic inflammation score (SIS)—were calculated from routine blood tests performed within four weeks prior to surgery. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan-Meier curves and Cox proportional hazard models.</div></div><div><h3>Results</h3><div>After a median follow-up of 61.3 months, 185 deaths (30.0 %) and 74 recurrences (12.0 %) were recorded. All indices demonstrated significant associations with five-year OS and DFS in univariate analysis. In multivariate analysis, PLR&gt;176.9 (HR 1.43; 95 % CI 1.06–1.94; <em>p</em> = 0.02) and LMR≤3 (HR 1.46; 95 % CI 1.8–1.99; p = 0.01) were independently associated with worse OS. For DFS, significant independent predictors of adverse outcomes included NLR&gt;2.95 (HR 1.58; 95 % CI 1.15–2.15; <em>p</em> = 0.004), PLR&gt;176.9 (HR 1.65; 95 % CI 1.20–2.26; <em>p</em> = 0.002), LMR≤3 (HR 1.57; 95 % CI 1.14–2.15; p = 0.006), SII&gt;529.6 (HR 1.46, 95 % CI 1.07–1.99; <em>p</em> = 0.02), and SIS 1–2 (HR 1.43, 95 % CI 1.03–2.06; <em>p</em> = 0.04).</div></div><div><h3>Conclusion</h3><div>Preoperative immunonutritional indices are independent prognostic markers in nonmetastatic colorectal cancer. Their integration with standard staging system could enhance risk stratification and guide personalized treatment.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102332"},"PeriodicalIF":2.4,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering upfront surgery for resectable pancreatic ductal adenocarcinoma: The role of risk stratification and neoadjuvant chemotherapy","authors":"Yoshitaro Shindo ,&nbsp;Hidenori Takahashi ,&nbsp;Hiroto Matsui ,&nbsp;Yukio Tokumitsu ,&nbsp;Masao Nakajima ,&nbsp;Yuta Kimura ,&nbsp;Mitsuo Nishiyama ,&nbsp;Yusaku Watanabe ,&nbsp;Shinobu Tomochika ,&nbsp;Yuki Nakagami ,&nbsp;Ryouichi Tsunedomi ,&nbsp;Michihisa Iida ,&nbsp;Tatsuya Ioka ,&nbsp;Hiroaki Nagano","doi":"10.1016/j.suronc.2025.102333","DOIUrl":"10.1016/j.suronc.2025.102333","url":null,"abstract":"<div><h3>Background</h3><div>The optimal treatment strategy for resectable pancreatic ductal adenocarcinoma (R-PDAC) remains controversial. In this study, we aimed to evaluate the impact of neoadjuvant chemotherapy (NAC) using gemcitabine plus nab-paclitaxel (GnP) or modified FOLFIRINOX (mFFX) compared with upfront surgery (UFS) in patients with R-PDAC.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included 125 patients diagnosed with R-PDAC at a single institution between 2010 and 2022. The patients were divided into UFS (n = 57) and NAC (n = 68) groups. Survival outcomes, perioperative factors, and prognostic variables were analyzed. Subgroup analysis was performed based on high-risk features, defined as elevated carcinoembryonic antigen (CEA) levels &gt;6 ng/mL and tumor size ≥25 mm.</div></div><div><h3>Results</h3><div>No significant differences were observed in overall survival (OS) and progression-free survival (PFS) between the entire UFS and NAC groups. However, in patients with high-risk features, NAC significantly improved OS compared with UFS (median survival 29.0 months vs. 10.6 months, respectively; P &lt; 0.0001). NAC was associated with reduced intraoperative blood loss and a lower lymph node positivity rate without increasing postoperative morbidity or mortality.</div></div><div><h3>Conclusions</h3><div>While NAC did not universally improve survival outcomes in R-PDAC, it significantly benefitted patients with poor prognostic indicators. These findings support a selective approach to NAC based on biological risk stratification rather than anatomical criteria alone. Future prospective studies are warranted to validate these observations and optimize individualized treatment strategies.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102333"},"PeriodicalIF":2.4,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for postoperative malignant progression of lower-grade gliomas: a systematic review and meta-analysis","authors":"Zhengmao Ge ,&nbsp;Guyu Jin ,&nbsp;Hongkang Wang ,&nbsp;Shimin Wang ,&nbsp;Xiaowei Fei ,&nbsp;Shuyang Li ,&nbsp;Lei Zhang ,&nbsp;Xiaofan Jiang ,&nbsp;Yanyu Zhang","doi":"10.1016/j.suronc.2025.102327","DOIUrl":"10.1016/j.suronc.2025.102327","url":null,"abstract":"<div><h3>Objectives</h3><div>The primary aim was to evaluate the risk factors for postoperative malignant progression of lower-grade glioma (LGG) in patients.</div></div><div><h3>Data sources</h3><div>PubMed, EMBASE, Web of Science and Cochrane Library were searched from database inception to August 2024.</div></div><div><h3>Eligibility criteria</h3><div>Quantitative and original studies reporting risk factors for postoperative malignant progression of LGGs were included.</div></div><div><h3>Results</h3><div>17 observational studies with 3810 glioma patients met the inclusion criteria. Factors including advanced age (HR 1.011, p = 0.042), contrast enhancement (HR 1.540, p = 0.001), rapid expanding speed (HR 4.525, p &lt; 0.001), location in insular lobe (HR 1.514, p = 0.020), eloquence involved (HR 2.413, p &lt; 0.001) and corpus callosum involved (HR 1.695, p = 0.002) were identified as risk factors of postoperative malignant progression of LGGs. High Karnofsky Performance Status (KPS) score (HR 0.955, p = 0.001), oligodendroglioma (HR 0.603, p &lt; 0.001), oligoastrocytoma (HR 0.693, p = 0.016), isocitrate dehydrogenase (IDH) mutation (HR 0.406, p = 0.004), 1p19q codeletion (HR 0.534, p &lt; 0.001), O⁶-methylguanine-DNA methyltransferase promoter (MGMTP) methylation (HR 0.539, p = 0.007), resection operation (HR 0.277, p &lt; 0.001) and high extent of resection (EOR) (HR 0.972, p = 0.038) were identified as factors that decreased the risk of postoperative malignant progression of LGGs.</div></div><div><h3>Conclusion</h3><div>This review identified multiple factors associated with the risk of postoperative malignant progression of LGGs, with moderate to high certainty of evidence supporting several key risk and protective factors. Surgeons should be aware of these factors and consider implementing more active treatment and surveillance measures for high-risk patients to improve prognosis.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102327"},"PeriodicalIF":2.4,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145534854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of the timing of adjuvant treatment initiation in patients with upfront resection of pancreatic cancer","authors":"Sydney McManus ,&nbsp;Aimée Galatas ,&nbsp;Sarah Hemelt ,&nbsp;Sanchit Sachdeva ,&nbsp;Kevin Sullivan ,&nbsp;Bolni Marius Nagalo ,&nbsp;Denise Danos ,&nbsp;Omeed Moaven","doi":"10.1016/j.suronc.2025.102329","DOIUrl":"10.1016/j.suronc.2025.102329","url":null,"abstract":"<div><h3>Introduction</h3><div>This study evaluates the association between timing of adjuvant chemotherapy and overall survival in resectable pancreatic ductal adenocarcinoma (PDAC). It also examines whether the adoption of modern chemotherapy regimens in recent years has influenced this relationship, reflecting evolving treatment practices.</div></div><div><h3>Methods</h3><div>Cases of resectable primary invasive PDAC were identified using the National Cancer Database (NCDB). Overall survival (OS) was visualized using Kaplan Meier survival plots and Cox proportional hazard models. Covariat adjustment and propensity score matched cohort were analyzed. The matched cohort was analyzed with Cox proportional hazard models and logistic models.</div></div><div><h3>Results</h3><div>31,949 patients were included in the study. 26.4 % received no chemotherapy, 66.4 % received chemotherapy within 12 weeks, and 7.2 % received chemotherapy after 12 weeks. There was significant improvement in mOS. Between 2015 and 2019, there was a significant difference in OS for patients receiving chemotherapy within 12 weeks, compared to &gt;12 weeks.</div></div><div><h3>Conclusion</h3><div>While adjuvant chemotherapy in patients with resectable PDAC is associated with improved OS compared to no adjuvant therapy, it is worth considering that those who are well enough to receive chemotherapy inherently have better prognoses. Importantly, the survival association persists regardless of the timing of chemotherapy initiation, suggesting that late administration of adjuvant chemotherapy may still be beneficial in appropriately selected patients.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102329"},"PeriodicalIF":2.4,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145528651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SCOUT® radar localization of non-palpable breast carcinomas versus traditional wire-based localization: a single center retrospective comparison","authors":"Åse Florholmen-Kjær ,&nbsp;Rica Mortensen ,&nbsp;Vegard Heimly Brun","doi":"10.1016/j.suronc.2025.102324","DOIUrl":"10.1016/j.suronc.2025.102324","url":null,"abstract":"<div><h3>Purpose</h3><div>Breast-conserving therapy requires a secure method to localize non-palpable lesions. The traditional and simple metal wire localization (WL) is challenged by more advanced and costly techniques that may have several advantages. We report the first European direct comparison between WL and SCOUT® Radar Localization (RL) comparing oncological and logistical benefits of implementing the new method in the treatment of non-palpable breast carcinomas including in situ lesions.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 150 breast cancer surgeries performed immediately before and after WL was replaced by RL in our unit. The last 50 wire-guided surgeries were compared to the initial 50 radar-guided surgeries (cohort I, implementation phase) and to the subsequent 50 radar-guided surgeries (cohort II, routine phase).</div></div><div><h3>Results</h3><div>All lesions and markers were successfully removed in all groups. No procedure-specific complications were registered. Of the 50 patients in the WL group, 8 % needed redo surgery due to positive margins, compared to 4 % in the RL groups (not statistically different). The histological margin was similar between the groups. The median time consumption during surgery was reduced by 26.5 min after establishing the radar localization method (p = 0.022). The resected tissue corresponded better with the marked area in the breast in the RL group (p = 0.026), as evaluated by a more central placement of the marker.</div></div><div><h3>Conclusions</h3><div>Radar localization of breast carcinomas is safe for women with non-palpable breast carcinomas including in situ lesions. The method reduces time consumption in the operating room and may give better surgical precision.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102324"},"PeriodicalIF":2.4,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}